Enveric Biosciences, Inc. financial data

Symbol
ENVB on Nasdaq
Location
4851 Tamiami Trail N, Suite 200, Naples, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 304 % -13%
Return On Assets -242 % -47.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 597K shares -94%
Common Stock, Shares, Outstanding 518K shares -94.2%
Entity Public Float 4.9M USD -31%
Common Stock, Value, Issued 5.18K USD -94.2%
Weighted Average Number of Shares Outstanding, Basic 313K shares +548%
Weighted Average Number of Shares Outstanding, Diluted 313K shares +548%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.38M USD -6.82%
General and Administrative Expense 6.13M USD +25.7%
Operating Income (Loss) -9.75M USD -10.3%
Nonoperating Income (Expense) 303K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.73M USD +1.09%
Income Tax Expense (Benefit) 1.73K USD
Net Income (Loss) Attributable to Parent -9.73M USD +1.26%
Earnings Per Share, Basic 23 USD/shares +74.9%
Earnings Per Share, Diluted 23 USD/shares +74.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 4.17M USD -3.98%
Property, Plant and Equipment, Net 197K USD -46.6%
Operating Lease, Right-of-Use Asset 9.61K USD -92.1%
Intangible Assets, Net (Excluding Goodwill) 169K USD
Goodwill 253K USD -82.8%
Assets 4.36M USD -8.94%
Accounts Payable, Current 684K USD +18.6%
Accrued Liabilities, Current 222K USD -12.2%
Liabilities, Current 906K USD +7.95%
Accumulated Other Comprehensive Income (Loss), Net of Tax -581K USD -8.59%
Retained Earnings (Accumulated Deficit) -113M USD -9.46%
Stockholders' Equity Attributable to Parent 3.46M USD -12.5%
Liabilities and Equity 4.36M USD -8.94%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.39M USD +7.96%
Net Cash Provided by (Used in) Financing Activities 4.45M USD -33.2%
Net Cash Provided by (Used in) Investing Activities -5.17K USD +99%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 518K shares -94.2%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.05M USD -49.5%
Deferred Tax Assets, Valuation Allowance 13.7M USD +6.37%
Depreciation 159K USD -6.69%
Payments to Acquire Property, Plant, and Equipment 5.17K USD -99%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -11.3M USD -14.6%
Operating Lease, Liability, Current 9.61K USD -91.3%
Deferred Tax Assets, Operating Loss Carryforwards 12M USD +10.3%
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 117M USD +8.73%
Amortization of Intangible Assets 169K USD -0.01%
Share-based Payment Arrangement, Expense 965K USD -33.5%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%